Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Merck & Co., Inc. Swiss Exchange

Equities

MRK

US58933Y1055

Delayed Swiss Exchange
Other stock markets
 10:06:38 05/12/2022 pm IST 		5-day change 1st Jan Change
400 CHF +388.82% Intraday chart for Merck & Co., Inc. -.--% -.--%
10:24am Merck: US approval for canine flu vaccine CF
25/06 Merck's Animal Health Unit Says USDA Approves Dog Flu Vaccine MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
USDA Approves Merck Animal Health's NOBIVAC NXT Canine Flu H3N2, The First and Only RNA-Particle Technology Vaccine for Canine Influenza
AQ
Merck: US approval for canine flu vaccine
CF
Merck's Animal Health Unit Says USDA Approves Dog Flu Vaccine
MT
Merck Animal Division's Dog Flu Treatment Gets Agriculture Department Approval
DJ
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
BU
China grants license to Merck's KEYTRUDA for stomach cancer treatment
RE
Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon...
Our Logo
Merck: FDA approves Capvaxive pneumococcal vaccine
CF
Merck: new FDA approval for Keytruda
CF
Merck - U.S. FDA Approves CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
AQ
FDA Approves Merck s KEYTRUDA plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma
AQ
Big tech still runs the show
Our Logo
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday
MT
Wall Street set for flat open after soft retail sales data
RE
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals
MT
Merck Gets FDA Approval for Keytruda Plus Carboplatin and Paclitaxel for Endometrial Carcinoma Treatment
MT
Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer
DJ
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
BU
US FDA approves Merck's pneumococcal vaccine for adults
RE
Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. MRK Stock
  5. News Merck & Co., Inc.